Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or Metastatic Malignant Mesothelioma

Trial Profile

Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or Metastatic Malignant Mesothelioma

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Imatinib (Primary) ; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Mar 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov
    • 04 Mar 2014 According to ClinicalTrials.gov record, planned end date changed from 1 Aug 2014 to 1 Aug 2015.
    • 04 Mar 2013 Planned end date changed from 1 Aug 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top